Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868361 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00868361 is a Phase 1 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 10 participants.
The verdict
NCT00868361, a Phase 1 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.
Interventions
- DRUG Talampanel (non-radiolabeled), [14C] Talampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868361
The ClinicalTrials.gov registry entry for NCT00868361 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talampanel (non-radiolabeled), [14C] Talampanel is the first listed.
NCT00868361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868361 about?
NCT00868361 is a clinical study titled "A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel". The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.
What is the current status of trial NCT00868361?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00868361?
The interventions under investigation include: Talampanel (non-radiolabeled), [14C] Talampanel (DRUG).
Who is sponsoring clinical trial NCT00868361?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.